Morgan Stanley
LPCN icon

Morgan Stanley’s Lipocine LPCN Stock Holding History

Morgan Stanley’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.59K Sell
574
-177
-24% -$1.54K ﹤0.01% 7161
2025
Q4 		$6.03K Buy
751
+176
+31% +$592 ﹤0.01% 7019
2025
Q3 		$1.64K Hold
575
– – ﹤0.01% 7341
2025
Q2 		$1.82K Sell
575
-2,000
-78% -$6.49K ﹤0.01% 7246
2025
Q1 		$8.19K Sell
2,575
-59
-2% -$228 ﹤0.01% 6863
2024
Q4 		$12.9K Hold
2,634
– – ﹤0.01% 6715
2024
Q3 		$11.8K Hold
2,634
– – ﹤0.01% 6666
2024
Q2 		$21.7K Buy
2,634
+1,912
+265% +$12K ﹤0.01% 6428
2024
Q1 		$3.75K Sell
722
-722
-50% -$2.81K ﹤0.01% 6953
2023
Q4 		$4.03K Buy
1,444
+722
+100% +$1.91K ﹤0.01% 7041
2023
Q3 		$2.15K Sell
722
-425
-37% -$1.79K ﹤0.01% 7117
2023
Q2 		$5.78K Sell
1,147
-234
-17% -$1.1K ﹤0.01% 6954
2023
Q1 		$7.47K Hold
1,381
– – ﹤0.01% 6964
2022
Q4 		$9.34K Sell
1,381
-709
-34% -$5.17K ﹤0.01% 6965
2022
Q3 		$16K Sell
2,090
-1,262
-38% -$14.1K ﹤0.01% 6888
2022
Q2 		$45K Buy
3,352
+951
+40% +$14.8K ﹤0.01% 6661
2022
Q1 		$55K Sell
2,401
-10,908
-82% -$228K ﹤0.01% 6661
2021
Q4 		$224K Sell
13,309
-11,469
-46% -$213K ﹤0.01% 6005
2021
Q3 		$459K Sell
24,778
-21,090
-46% -$465K ﹤0.01% 5552
2021
Q2 		$1.09M Buy
45,868
+44,092
+2,483% +$1.04M ﹤0.01% 5028
2021
Q1 		$46K Buy
1,776
+155
+10% +$4.47K ﹤0.01% 6385
2020
Q4 		$37K Buy
1,621
+1,324
+446% +$31.9K ﹤0.01% 6249
2020
Q3 		$7K Buy
297
+209
+238% +$5.55K ﹤0.01% 6371
2020
Q2 		$2K Hold
88
– – ﹤0.01% 6452
2020
Q1 		$1K Sell
88
-1
-1% -$8 ﹤0.01% 6467
2019
Q4 		$1K Hold
89
– – ﹤0.01% 6570
2019
Q3 		$4K Sell
89
-14
-14% -$562 ﹤0.01% 6397
2019
Q2 		$3K Sell
103
-29
-22% -$895 ﹤0.01% 6406
2019
Q1 		$5K Buy
132
+14
+12% +$430 ﹤0.01% 6322
2018
Q4 		$3K Hold
118
– – ﹤0.01% 6376
2018
Q3 		$3K Sell
118
-5,151
-98% -$127K ﹤0.01% 6511
2018
Q2 		$116K Sell
5,269
-10
-0.2% -$238 ﹤0.01% 5702
2018
Q1 		$138K Buy
5,279
+1,217
+30% +$33.9K ﹤0.01% 5616
2017
Q4 		$237K Buy
4,062
+3,905
+2,487% +$243K ﹤0.01% 5350
2017
Q3 		$11K Sell
157
-581
-79% -$42K ﹤0.01% 6154
2017
Q2 		$50K Sell
738
-711
-49% -$46.4K ﹤0.01% 5858
2017
Q1 		$95K Sell
1,449
-1,929
-57% -$125K ﹤0.01% 5622
2016
Q4 		$211K Buy
3,378
+3,040
+899% +$192K ﹤0.01% 5336
2016
Q3 		$25K Sell
338
-746
-69% -$46.2K ﹤0.01% 5840
2016
Q2 		$56K Sell
1,084
-547
-34% -$84.7K ﹤0.01% 5491
2016
Q1 		$281K Buy
1,631
+1,235
+312% +$211K ﹤0.01% 4778
2015
Q4 		$87K Sell
396
-3,290
-89% -$690K ﹤0.01% 5480
2015
Q3 		$741K Buy
3,686
+3,604
+4,395% +$834K ﹤0.01% 4344
2015
Q2 		$12K Buy
+82
New +$10.2K ﹤0.01% 6263
2015
Q1 		– Sell
-313
Closed -$28K – 6603
2014
Q4 		$28K Buy
313
+312
+31,200% +$26.4K ﹤0.01% 5977
2014
Q3 		$0 Hold
1
– – ﹤0.01% 6617
2014
Q2 		$0 Buy
+1
New +$120 ﹤0.01% 6559

Other funds holding LPCN

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $318M AUM
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Morgan Stanley's LPCN Position: Q1 2026 in Review

Morgan Stanley reduced its Lipocine (LPCN) stake by 24% in Q1 2026, selling an estimated $1.54K and leaving 574 shares worth $4.59K. The position accounts for ﹤0.01% of the portfolio, ranked #7161.

Morgan Stanley first reported a position in LPCN in Q2 2014 and has held it in 47 quarters since. The position peaked at $1.09M in Q2 2021. 47 funds tracked by Wall St. Rank hold LPCN as of Q1 2026.

  • Morgan Stanley held 574 shares of Lipocine worth $4.59K as of Q1 2026.
  • Morgan Stanley sold 177 Lipocine shares in Q1 2026, an estimated $1.54K.
  • Lipocine made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #7161 holding.
  • Morgan Stanley first reported a position in Lipocine in Q2 2014 and has held it in 47 quarters since.
  • Morgan Stanley's Lipocine position peaked at $1.09M in Q2 2021.
  • 47 funds tracked by Wall St. Rank held Lipocine as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.